Avidicure
6 known investors
Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a γδ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.
Founders & leadership
RF
Robert FrieseninCSO & Co-Founder
Investors · 6
Funding
SEC filings, press & company announcements$50M disclosed across 1 of 3 rounds · 2025
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Avidicure do?
- Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a γδ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.
- Who founded Avidicure?
- Avidicure was founded by Robert Friesen.
- Who are Avidicure's investors?
- Avidicure's investors include BioGeneration Ventures, EQT Life Sciences, BOM, Curie Capital, Kurma Partners, V-Bio Ventures.
- How much funding has Avidicure raised?
- Avidicure has disclosed $50M raised across 1 of its 3 known rounds.